
Unlearn AI is a biotechnology company that leverages artificial intelligence and patient digital twin technology to optimize clinical trial design and efficiency.
Its core technology is building patient digital twins—a high-precision AI predictive model trained on historical data that simulates the natural progression of a patient's disease without intervention.
The TrialPioneer platform primarily integrates intelligent search, historical data validation, and trial scenario simulation, supporting an end-to-end design-to-analysis workflow.
Benefits include reducing the number of control-arm patients recruited, shortening trial timelines, lowering costs, and enabling more data-driven trial design and decision-making.
According to public information, its technology has been applied across neuroscience (e.g., Alzheimer's disease, amyotrophic lateral sclerosis), immunology, metabolic diseases, cardiovascular, and other areas.
The solution offers flexible deployment options, allowing sponsors to build customized AI models in cloud or on-premises environments using their own data.
According to the company, its TwinRCTs™ methodology has received a favorable qualification opinion from the European Medicines Agency (EMA) and is recognized by the U.S. FDA.
Primarily aimed at pharmaceutical and biotech R&D and clinical teams, academic research institutions, and contract research organizations (CROs) responsible for clinical trial design and optimization.

Thinking Machines AI is a company focused on AI research and product development, offering the Tinker model fine-tuning API platform. The platform gives researchers and developers deep control over model training while managing the underlying infrastructure, lowering the barrier to customizing large language models and promoting more democratic, collaborative AI development.

Tempus AI is a precision medicine company that uses artificial intelligence and data platforms to integrate multimodal medical data, delivering data-driven solutions for clinical decision support, medical research and drug development.